Archive | BIOgraph RSS feed for this section

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P [...]

Leave a comment Continue Reading →

Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%

The NASDAQ Biotechnology Index IBB ($122.30)  is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors [...]

Comments Off Continue Reading →

Alere Inc.(ALR) : Where is the bottom and what went wrong?

ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an opportunity to get out in the 40′s with a [...]

Comments Off Continue Reading →

Rayno Life Science Portfolio Update: ALR, GPRO, REGN

Consolidation Continues in Mid Cap DX Companies: Bull Market in Biotech Hits New Highs Our Life Science Tools and Diagnostics Portfolio had a nice hit today with GenProbe up 18.75% on the Agreement that it would be sold to Hologic (HOLX $18.82 down 11.2%) for $3.7B or $82.75/sh. This is a strategic deal that builds [...]

Comments Off Continue Reading →

Rayno Life Science Portfolio: CBST, GILD,HGSI, REGN SQNM

Biotech Rally Ignited By Clinical News and M&A Theme The biotech sector roared back today with major ETF’s IBB ($122) up 2.4% and XBI ($78.6) up 5.1 % driven primarily by Gilead (GILD $52.23) up 12 % and other large caps like Regeneron (REGN $127) up 2.5%. Gilead (GILD) was up on clinical results from their [...]

Comments Off Continue Reading →

Risk Off: Profit Taking, Spain and Jobs Data//BIO Update April 11

Nice Recovery in biotech today with our mid-cap index up almost 1%. Without doing a lot of detailed analysis it looks like stocks that have major institutional sponsors are rallying. Smaller caps without significant volume are still lagging. Two high fliers : Vivus (VVUS $22.15) and Medivation (MDVN $75.24) regained some composure after a bashing [...]

Comments Off Continue Reading →